FDA says products were shipped to stores between June and September
Family Dollar voluntarily recalled dozens of over-the-counter drugs, products and medical devices sold at its stores because they had been stored at improper temperatures, according to the Food and Drug Administration late Tuesday.
On the FDA’s website, the regulator said products affected by the recall were stored “outside of labeled temperature requirements by Family Dollar and inadvertently shipped to certain stores on or around June 1, 2023 through September 21, 2023.” Brands affected by the recall include Procter & Gamble’s PG, +0.99% Crest, Vicks and Pepto Bismol; Colgate CL, +0.26% ; Johnson & Johnson Inc.’s JNJ, -0.11% Tylenol and Listerine; and Bayer’s BAYN, +3.04% Aleve, according to a list provided by the FDA.
The items were sold at stores in Alabama, Arkansas, Arizona, California, Colorado, Florida, Georgia, Idaho, Kansas, Louisiana, Mississippi, Montana, North Dakota, Nebraska, New Mexico, Nevada, Oklahoma, Oregon, South Dakota, Texas, Utah, Washington and Wyoming, between June 1 and Oct. 4, the FDA said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Family Dollar recalls OTC drugs, products in 23 states over incorrect temperature storageWallace Witkowski came to MarketWatch from the Associated Press in New York, where he covered the business of Big Pharma, after covering FDA regulation of many of the same companies, as well as medical devices, in the Washington, D.C., area. Based in San Francisco, his current focus is on the more exciting world of semiconductors, videogames and cybersecurity, when he's not churning out earnings coverage. Follow him on Twitter at: wmwitkowski.
Read more »
Best electric toothbrush deals: Save on Colgate, Quip and Oral-BWe've picked out all the best electric toothbrush deals available right now with something for every budget and need listed.
Read more »
Alnylam to scrap sNDA for patisiran after receiving FDA complete response letterCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Read more »
Alnylam Stock Is Dropping on Surprising FDA RejectionDrugmaker Alnylam wanted to expand approval of its drug Onpattro, but the Food and Drug Administration rejected the application even after an outside...
Read more »
FDA Adds Warning To Ozempic Label About Ileus, Intestinal BlockageI am a writer, journalist, professor, systems modeler, computational, AI, and digital health expert, medical doctor, avocado-eater, and entrepreneur, not always in that order. Currently, I am a Professor of Health Policy and Management at the City University of New York (CUNY) School of Public Health, Executive Director of PHICOR (PHICORteam) and Center for Advanced Technology and Communication in Health (CATCH), and founder and CEO of Symsilico. My previous positions include serving as Profess
Read more »
Novavax ships millions of updated COVID-19 vaccine doses after FDA clearanceVaccine manufacturer Novavax Inc. has announced the shipment of millions of doses of its updated COVID-19 vaccines to distributors following approval from U.S. regulators.
Read more »